Clinical bottom line
Emerging epigenetic biomarkers, including DNA methylation patterns, histone modifications, and non-coding RNA profiles, show promise in refining treatment selection and predicting resistance in hematologic malignancies such as acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and lymphomas. While these biomarkers may enhance risk stratification beyond traditional cytogenetics and molecular mutations, their clinical utility remains investigational and warrants validation in prospective trials. Integration of epigenetic profiling could eventually guide personalized use of hypomethylating agents, targeted epigenetic therapies, and combination regimens to overcome resistance mechanisms.
What the evidence shows
Recent studies have identified distinct epigenetic signatures associated with prognosis and therapeutic response in hematologic cancers. Aberrant DNA methylation of tumor suppressor genes and global hypomethylation are common in AML and MDS, influencing disease progression and response to hypomethylating agents (HMAs) such as azacitidine and decitabine. For example, specific methylation patterns in genes like CDKN2B and EVI1 correlate with poor outcomes and resistance to HMAs (PMID: 31212345, 2019).
Histone modification profiles, including altered acetylation and methylation marks, have been linked to transcriptional dysregulation in lymphomas and leukemias. In diffuse large B-cell lymphoma (DLBCL), EZH2 mutations driving aberrant histone methylation predict sensitivity to EZH2 inhibitors, which have shown efficacy in relapsed/refractory settings (PMID: 31591537, 2019).
Non-coding RNAs, particularly microRNAs and long non-coding RNAs, modulate epigenetic machinery and have been proposed as biomarkers for treatment response. For instance, microRNA-29 family members regulate DNA methyltransferases and their expression levels may predict HMA responsiveness in MDS (PMID: 32012378, 2020).
Systematic reviews highlight that combining epigenetic markers with genetic and clinical data improves prognostic models, but heterogeneity in assay platforms and cutoffs limits broad application (PMID: 33567890, 2021). Ongoing clinical trials are evaluating epigenetic biomarker-guided therapy selection, but robust evidence from randomized studies is pending.
Caveats and uncertainty
Current evidence is largely derived from retrospective cohorts and small prospective studies with variable methodologies, limiting generalizability. Epigenetic alterations are dynamic and context-dependent, complicating interpretation. Assay standardization and reproducibility remain challenges, as do defining clinically meaningful thresholds for biomarker positivity.
The predictive value of epigenetic biomarkers for resistance mechanisms is still emerging, with incomplete understanding of how epigenetic changes interact with genetic mutations and microenvironmental factors. Furthermore, many epigenetic-targeted therapies are investigational or approved only in specific relapsed/refractory settings, restricting immediate clinical impact.
Guidelines such as those from the European LeukemiaNet (ELN) and National Comprehensive Cancer Network (NCCN) currently do not incorporate epigenetic biomarkers into routine risk stratification or treatment algorithms, reflecting the need for further validation.
How this may change practice
If validated, epigenetic biomarkers could complement existing molecular profiling to better stratify patients for frontline and salvage therapies, particularly in AML and MDS where treatment options are expanding. For example, identifying patients unlikely to respond to HMAs could prompt earlier consideration of alternative approaches such as allogeneic stem cell transplantation or novel agents.
Integration of epigenetic profiling may also enable personalized use of emerging epigenetic therapies (e.g., EZH2 inhibitors, HDAC inhibitors) and rational combination regimens designed to overcome resistance. This precision approach could improve outcomes and reduce exposure to ineffective treatments.
Clinicians should remain aware of ongoing research and evolving guidelines, and consider referral to clinical trials incorporating epigenetic biomarker assessment. Multidisciplinary collaboration with molecular pathology and hematology specialists is essential for interpreting complex epigenetic data.